![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » VALEANT BEGINS STUDY OF HEPATITIS C ANTIVIRAL
VALEANT BEGINS STUDY OF HEPATITIS C ANTIVIRAL
Valeant Pharmaceuticals announced it has begun enrolling patients in a Phase IIb study of its antiviral compound, taribavirin, an oral nucleoside (guanosine) analog, for the treatment of chronic hepatitis C in conjunction with a pegylated interferon.
The trial is a multicenter, randomized, parallel, open-label study in 260 treatment-naïve, genotype 1 patients. The study will evaluate taribavirin doses of 20, 25 and 30 mg/kg per day in combination with pegylated interferon alfa-2b. There also will be a control group taking ribavirin and pegylated interferon alfa-2b.
Valeant will perform analyses of the study data after all patients have reached the week-12 time point, which is the primary endpoint of the study. The results at week 12 are typically predictive of a full 48-week treatment course. Based on the 12-week data, the company will decide whether to begin another Phase III study at a more appropriate dose than used in the previous VISER studies.
Additionally, if the week-12 data are encouraging, the company intends to continue the current study for a full 48-week treatment course with a posttreatment follow-up at week 72. The 12-week results are expected to be available by the end of the year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct